🇺🇸 FDA
Patent

US 11229687

TPP-1 formulations and methods for treating CLN2 disease

granted A61KA61K38/4813A61K47/02

Quick answer

US patent 11229687 (TPP-1 formulations and methods for treating CLN2 disease) held by BIOMARIN PHARMACEUTICAL INC. expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
BIOMARIN PHARMACEUTICAL INC.
Grant date
Tue Jan 25 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
18
CPC classes
A61K, A61K38/4813, A61K47/02, A61K9/0048, A61K9/0085